Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve Approval of standalone ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has informed BSE that its Board of Directors will meet on 12 November 2025 at 4:00 p.m. at the Corporate Office in Chembur, Mumbai. The main agenda is to consider and approve the Standalone Unaudited Financial Results for the quarter and half year ended 30 September 2025 (Q2 FY26). Any other matter with the Chairman's permission may also be taken up. The trading window for directors, officers and designated employees has been closed since 1 October 2025 and will reopen 48 hours after the results are publicly announced, in line with insider trading rules.
This is a routine pre-results intimation with no financial numbers disclosed. Shareholders should watch for the Q2/H1 FY26 results announcement, which could move the stock depending on performance versus expectations.